TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00350948
Drug: Liposomal Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1 of 28 Day Cycle. 50 mg/m2
Study: NCT02458755
Drug: High-dose statin: Atorvastatin 40mg or Rosuvastatin 20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40mg or Rosuvastatin 20mg
Study: NCT01183559
Drug: 5 Fluorouracil (FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU 225 mg/m2/day continuous infusion over96 hours during radiation therapy
Study: NCT00515801
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsules, single dose
Study: NCT01556607
Drug: MDT-637
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled doses of MDT-637 over a 24 hour period at 3 visits
Study: NCT01556607
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01175018
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.67 ml of NaCl 0.9% solution given subcutaneously daily for 14 days
Study: NCT04179734
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaenous injection.
Study: NCT00550758
Drug: Methachoine
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhalation of triple-concentration increments (0.06 to13.9mg/ml/methacholine)
Study: NCT00958334
Drug: Proellex®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg daily (two 12.5 mg capsules)
Study: NCT01936805
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A 40 mg loading dose of rosuvastatin was administrated 24 h before the PCI.
Study: NCT04114292
Drug: Tauroursoursodeoxycholic acid, brand name Tudcabil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosed in capsules containing 250 or 500mg of TUDCA for a total dose of 1.75-2g/day
Study: NCT03435848
Drug: BST-236
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 to 4 courses
Study: NCT00818545
Drug: ER4017 (hydroxypropyltetrahydropyrantriol)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream, 10%, each day during 3 months
Study: NCT00818545
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03359356
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total of 24 doses
Study: NCT00151489
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00752635
Drug: Norgestimate-ethinyl estradiol; Cyproterone acetate-ethinyl estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03944447
Drug: Cannabis, Medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be given medical cannabis recommendations and certifications commensurate with the state law in which the encounter occurs. The variations in mechanisms between the states for recommending, registering, certifying, and developing mandated treatment plans or doses will be adhered to; however, variations in state law and cannabis programs should not cause variation in the study design because the end-result is still the same with patients being treated with medical cannabis.
Study: NCT01878292
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose matched placebo tablets, once per day, oral administration.
Study: NCT02347098
Drug: standard statin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: The standard statin therapy of 40-80mg oral daily dose of Atorvastatin or other equivalent types of statin to lower LDL in blood for both randomized groups.
Study: NCT04640272
Drug: RBM-007
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection
Study: NCT04114149
Drug: iv opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with iv opioid if postoperative pain intensity according to NRS (numeric rating scale) ≥ 3.
Study: NCT00276926
Drug: STI571
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03126747
Drug: BAY86-5300_YAZ-Flex
Normalized name: Ed Flex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with endometriosis-associated pelvic pain and/or dysmenorrhea are enrolled solely after the physician's decision of YazFlex treatment in routine clinical practice.
Study: NCT00323882
Drug: MDX-010
Normalized name: hydrocortisone acetate Topical Gel [Cortisil MDX]
Approvals — FDA: no, EMA: no, PMDA: no
Description: selected dose administered IV every 3 weeks
Study: NCT01494532
Drug: placebo/L-dopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo as adjunctive therapy with L-dopa
Study: NCT01273051
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine will be administered at a dose of 825 mg/m2 bid during radiotherapy treatment
Study: NCT01230307
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo loading dose will be given followed by 2 placebo tablets daily for 6 months.
Study: NCT03714685
Drug: Firibastat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Firibastat (QGC001) 500 mg
Study: NCT00898807
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily for 9 weeks
Study: NCT01647451
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two i.v. (intravenous) doses administered 6 weeks apart.
Study: NCT00933673
Drug: L-asp, DXM, IFO, VP-16, DDP
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-asp 6000 u/m2; DXM 40 mg d1-4; IFO 1200mg/m2 d1-4; Mesna 400mg, tid, d1-4; VP-16 60 mg/m2 d1-4; DDP 20mg/m2 d1-4; q3w. Efficacy was evaluated every two cycles. If patients hadn't diseases progression, two more cycles and radiation would be administered.
Study: NCT02456844
Drug: Montelukast, Flurbiprofen, Midazolam, Digoxin, Pravastatin and BMS-986142
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Montelukast 10-mg tablet: On Days 1 and 8,Single oral dose~2. Flurbiprofen 50-mg tablet: On Days 1 and 8,Single oral dose~3. Midazolam syrup 2.5 mL × 2 mg/mL (5 mg): On Days 1 and 8,Single oral dose~4. Digoxin (Lanoxin®) 0.25 mg tablet: On Days 1 and 8,Single oral dose~5. Pravastatin 40-mg tablet: On Days 1 and 8,Single oral dose~6. BMS-986142: On Days 6 through 12.
Study: NCT02456844
Drug: Methotrexate, Leucovorin and BMS-986142
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Methotrexate (MTX) single oral dose of 3 × 2.5-mg tablet (Days 1 and 8)~2. Leucovorin single oral dose of 15-mg tablet (Days 2 and 9; 24 hours after MTX administration)~3. BMS-986142 on Days 6 through 10.
Study: NCT00582673
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01388660
Drug: Plavix/Astrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous Administration of Plavix (75 mg of Clopidogrel) and Astrix (100 mg of Aspirin), 2 tablets once daily for Period I \& II Day 1 (crossover manner)
Study: NCT01527890
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous patient-controlled analgesia
Study: NCT01499602
Drug: LNG-IUS; Mirena; Bayer Schering Pharma Oy, Finland
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial release rate of 20µg Levonorgestrel per day for one year follow up.
Study: NCT01626391
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets will be administered twice daily (b.i.d.) for 4 weeks. The placebo tablets include 4 mg of TRx0237 as a urinary and faecal colourant to maintain blinding; hence, the placebo group will receive a total of 8 mg/day of TRx0237.
Study: NCT00597480
Drug: rhGH norditropine simple Xx
Approvals — FDA: no, EMA: no, PMDA: no
Description: the dose to achieve a treat-to target value of IGF-1 levels within a +1.5 to +2.5 SDS interval (starting dose, 0.067 mg/kg/day)
Study: NCT02740647
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 ml of 0.9% sodium chloride three times a day
Study: NCT00056407
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After successful completion of the placebo run-in phase, subjects who continue to meet eligibility requirements will be randomized into the double-blind phase of the study and issued a 6-month supply of study drug. Subjects will self-administer study drug once daily orally for up to 4 years.
Study: NCT01571791
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: to receive saline infusion and intravenous fentanyl boluses, at 30 min before induction of anesthesia
Study: NCT01571791
Drug: Ketorolac-Lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: receive ketorolac-lidocaine infusion and intravenous saline boluses , at 30 min before induction of anesthesia
Study: NCT02411903
Drug: rosuvastatin and clopidogrel
Normalized name: rosuvastatin and ezetimibe
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose: rosuvastatin 20mg/d plus clopidogrel 75mg/d for 9 months.
Study: NCT03391284
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORAL
Study: NCT00530309
Drug: GSK716155 for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK716155 will be available with doses of 15 milligrams once a week, 30 milligrams once a week, 50 milligrams biweekly or 100 milligrams once every four weeks.
Study: NCT00676676
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone atch delivering 300mcg daily for 8-weeks
Study: NCT00751400
Drug: Naproxen Sodium ER (BAYH6689)
Normalized name: naproxen Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consumer use of Extended Release Naproxen Sodium
Study: NCT00530309
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will also receive placebo.
Study: NCT03480321
Drug: PMR 150 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two extended-release tablets (PMR 150 mg) at 08:00, single oral dose (total daily dose of 300 mg)
Study: NCT03480321
Drug: PMR 200 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two extended-release tablets (PMR 200 mg/tablet) at 08:00, single oral dose (total daily dose of 400 mg)
Study: NCT02667054
Drug: RX0041 4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthetic
Study: NCT02316535
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: adjuvant chemotherapy;
Study: NCT03799250
Drug: Ringer lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between fluid maintenance in PACU compared to a bolus based goal directed hemodynamic therapy in the PACU
Study: NCT02667054
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator
Study: NCT02667054
Drug: RX0041 8%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthetic
Study: NCT02191254
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02037295
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills orally four times per day for 12 days
Study: NCT03410173
Drug: Taurine
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03410173
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00952497
Drug: Cisplatin, Capecitabine, Telatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive: Chemotherapy (capecitabine and cisplatin) and telatinib Capecitabine will be administered (1000 mg/m2) twice daily for 14 days followed by a 7-day rest period. Cisplatin (80 mg/m2) will be given as a 1-3 hour infusion once every 3 weeks. Telatinib (3 tablets) will be administered orally, twice daily as a continuous administration. After a maximum of 6 cycles of cisplatin, subjects continue with capecitabine and telatinib or monotherapy with either study drug,depending on the toxicity experienced by the subject, until disease progression.
Study: NCT01131676
Drug: Placebo BI 10773 high dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets identical to BI 10773
Study: NCT01131676
Drug: Placebo BI 10773 low dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets identical to BI 10773
Study: NCT03129321
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00114049
Drug: GW406381
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00067028
Drug: Ara-C 0.75 g/m^2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 g/m\^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle.
Study: NCT00067028
Drug: Ara-C 1 g/m^2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/m\^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle.
Study: NCT01094769
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: lactose capsule taken once daily
Study: NCT00649987
Drug: VoSpire® ER Tablets 8 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8mg, single dose fed
Study: NCT01111851
Drug: MK0999
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.V. infusion of MK0999 containing \~100 MBq (\~3 mCi) containing ≤ 5 ug of MK0999)
Study: NCT03070470
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered orally)
Study: NCT02281591
Drug: R-licarbazepine
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules containing 225 mg
Study: NCT03982368
Drug: rhNGF 20 μg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: one drop of rhNGF 20 μg/ml will be instilled in both eyes three times daily (every 6-8 hours)
Study: NCT03982368
Drug: rhNGF 20 μg/ml + vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: one drop of rhNGF 20 μg/ml will be instilled in both eyes two times daily plus one drop (40 μL) of vehicle will be instilled in both eyes once daily (every 6-8 hours).~rhNGF will be instilled in the morning and in the evening while the vehicle will be instilled in the afternoon.
Study: NCT02006342
Drug: Regular Insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01472263
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules 3 times a day. The capsules have the same shape, color and form as the treatment group, and are identified by envelope numbers.
Study: NCT01823042
Drug: azathioprine+enteral nutrition
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01823042
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01333150
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One single dose of placebo
Study: NCT00965874
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: serum salin
Study: NCT03880266
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-saturated 100% polypropylene, nonwoven, fabric cloth
Study: NCT00613145
Drug: Capecitabine and Sorafenib
Approvals — FDA: no, EMA: no, PMDA: no
Description: During Cycle 1, patients will receive capecitabine alone for the first 7 days (Cohort A will receive 750 mg/m2 of capecitabine twice daily). For Days 8-14 of Cycle 1, patients will receive capecitabine (750 mg/m2 twice daily for Cohort A) combined with sorafenib (400 mg twice daily); on Days 15-21 of Cycle 1, patients will receive sorafenib alone (400 mg twice daily). Beginning with Day 1 of Cycle 2 and all treatment cycles thereafter, patients will be dosed as follows:~Cohort A will receive sorafenib orally at 400 mg twice daily for 21 days, and capecitabine orally at 750 mg/m2 twice daily for the first 14 days of a 21-day treatment cycle.
Study: NCT00613145
Drug: Capecitabine and Sorafenib
Approvals — FDA: no, EMA: no, PMDA: no
Description: During Cycle 1, patients will receive capecitabine alone for the first 7 days Cohort B will receive 1000 mg/m2 of capecitabine twice daily for the first 7 days of Cycle 1). For Days 8-14 of Cycle 1, patients will receive capecitabine (1000 mg/m2 twice daily for Cohort B) combined with sorafenib (400 mg twice daily for both cohorts); on Days 15-21 of Cycle 1, patients will receive sorafenib alone (400 mg twice daily). Beginning with Day 1 of Cycle 2 and all treatment cycles thereafter, patients will be dosed as follows: Cohort B will receive sorafenib orally at 400 mg twice daily for 21 days, and capecitabine orally at 1000 mg/m2 twice daily for the first 14 days of a 21-day treatment cycle.
Study: NCT01324258
Drug: GSK1120212
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part1 and Part2
Study: NCT03227900
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intragastric infusion of water for injections
Study: NCT01667029
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03161405
Drug: TAK-906 Maleate
Normalized name: maleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-906 capsule
Study: NCT01074190
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: A basal infusion rate for the PCEA will be set at 8 mL/h with patient administered boluses of 8 mL every 10 minutes and a one hour limit of 32 mL. Breakthrough pain in all groups will be managed using anesthesiologist administered boluses of bupivacaine 1.25 mg/mL without fentanyl.
Study: NCT01074190
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: A basal infusion rate for the PCEA will be set at 8 mL/h with patient administered boluses of 8 mL every 10 minutes and a one hour limit of 32 mL. Breakthrough pain in all groups will be managed using anesthesiologist administered boluses of bupivacaine 1.25 mg/mL without fentanyl.
Study: NCT01074190
Drug: Group 3
Normalized name: Chlamydophila psittaci biogroup 3 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: A basal infusion rate for the PCEA will be set at 8 mL/h with patient administered boluses of 8 mL every 10 minutes and a one hour limit of 32 mL. Breakthrough pain in all groups will be managed using anesthesiologist administered boluses of bupivacaine 1.25 mg/mL without fentanyl.
Study: NCT00959868
Drug: OGX-427
Approvals — FDA: no, EMA: no, PMDA: no
Description: OGX-427 drug product is in 25mg/mL injection in a mannitol-phosphate buffer solution packaged to deliver at least 8mL volume from a 10mL Type I, clear glass vial (ammonium sulfate treated) with Teflon coated bromobutyl rubber stopper and sealed with an aluminum, red, flip-off over seal. The drug product is aseptically compounded and sterilized via sterile filtration prior to aseptic filling.
Study: NCT01399788
Drug: Myrin P Forte
Normalized name: Erythroped Forte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet containing Rifampicin, Isoniazid, Ethambutol and Pyrazinamide, given once daily, single dose
Study: NCT01399788
Drug: Single drug references
Approvals — FDA: no, EMA: no, PMDA: no
Description: containing Rifampicin, Isoniazid, Ethambutol and Pyrazinamide as single agents
Study: NCT01500278
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * Active substance: Methotrexate~* Pharmaceutical form: oral tablet~* Concentration: 15-25 mg/week~* Route of Administration: MTX orally
Study: NCT01698164
Drug: estradiol plus MPA
Normalized name: polyurethane-34 (55 MPA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants are given estradiol and synthetic progestin.
Study: NCT01698164
Drug: estradiol plus progesterone
Normalized name: ESTRADIOL/PROGESTERONE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants are given estradiol and natural progesterone.
Study: NCT01285115
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.
Study: NCT01285115
Drug: KyungBangn-Gamisoyosan-x-gwarip
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.
Study: NCT02818543
Drug: LYC-30937
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01285115
Drug: KyungBangn Gamisoyosan
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.
Study: NCT03024515
Drug: opioids titration
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Practice Arm
Study: NCT00351676
Drug: Optimizing therapeutic treatments
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01581658
Drug: BI10773
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI10773 medium dose tablet single dose
Study: NCT01421277
Drug: Statin Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator's choice of any statin.
Study: NCT04975035
Drug: Zolodine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collect 200 patients who meet the criteria into the group. After enrollment, according to the principle of cross dressing change, the attending physician can decide the dressing change method according to the patient's condition, individual condition and other factors; within 2-4 weeks, the original antipsychotics should be gradually stopped, and Zoladine capsules will be gradually added to the target The dose is 120-160mg/d, orally 1-2 times a day, with meals.
Study: NCT03911414
Drug: Open-label Treatment with Omega-3 Fatty Acids + Inositol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label Treatment with Omega-3 Fatty Acids + Inositol
Study: NCT03911414
Drug: Open-label Treatment with N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label Treatment with N-acetylcysteine
Study: NCT03682653
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: a single dose of Azithromycin will be administered to infants between their 8-27th days of life
Study: NCT03682653
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single dose of Placebo will be administered to infants between their 8-27th days of life
Study: NCT04225923
Drug: NPC-21 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered via an approximately 60-minute intravenous infusion on Day 1 and at Week 4, 8, 12
Study: NCT00002788
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04198363
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin Tablets
Study: NCT04342650
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150mg placebo tablets
Study: NCT03649477
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: three times per day with meals
Study: NCT01597245
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC